NCT03388645View on ClinicalTrials.gov

Challenge Infection of Healthy Adult Volunteers With RSV A2

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

November 15, 2019

Study Completion Date

December 6, 2019

Conditions
Upper Respiratory Tract Infections
Interventions
BIOLOGICAL

10^6.3 PFU of RSV A2

Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.

BIOLOGICAL

10^7 PFU of RSV A2

Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03388645 - Challenge Infection of Healthy Adult Volunteers With RSV A2 | Biotech Hunter | Biotech Hunter